Michael Lane - 06 Aug 2025 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Signature
/s/ Lily J. Lu, Attorney-in-Fact for Michael Lane
Issuer symbol
IDXX
Transactions as of
06 Aug 2025
Net transactions value
-$2,956,211
Form type
4
Filing time
08 Aug 2025, 20:37:18 UTC
Previous filing
18 Feb 2025
Next filing
17 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lane Michael Executive Vice President ONE IDEXX DRIVE, WESTBROOK /s/ Lily J. Lu, Attorney-in-Fact for Michael Lane 08 Aug 2025 0001740689

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Options Exercise $266,125 +1,286 +18% $206.94 8,418 06 Aug 2025 Direct F1
transaction IDXX Common Stock Options Exercise $2,057,558 +7,125 +85% $288.78 15,543 06 Aug 2025 Direct
transaction IDXX Common Stock Sale $3,533,810 -5,631 -36% $627.56 9,912 06 Aug 2025 Direct F2
transaction IDXX Common Stock Sale $1,557,418 -2,480 -25% $627.99 7,432 06 Aug 2025 Direct F3
transaction IDXX Common Stock Sale $188,666 -300 -4% $628.89 7,132 06 Aug 2025 Direct F4
holding IDXX Common Stock 592 06 Aug 2025 by spouse F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise $0 -1,286 -100% $0.000000 0 06 Aug 2025 Common Stock 1,286 $206.94 Direct F6
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise $0 -7,125 -100% $0.000000 0 06 Aug 2025 Common Stock 7,125 $288.78 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a total of 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.
F2 Represents the weighted average price of the shares sold ranging from a low of $626.70 to a high of $627.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3 Represents the weighted average price of the shares sold ranging from a low of $627.70 to a high of $628.62 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4 Represents the weighted average price of the shares sold ranging from a low of $628.82 to a high of $628.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F5 Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.
F6 Grant of option to buy 8,366 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2020.
F7 Grant of option to buy 7,125 shares of Issuer common stock that became exercisable in four annual installments beginning February 14, 2021.